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Until recently, there were very little data on the effects of antiepileptic drug (AED)
exposure in utero. However, in the past two decades, data from several prospective pregnancy
registries have significantly increased the understanding of the critical risks for major congenital
malformations associated with several AEDs (Gerard & Meador, 2015). This research examined
the risks associated with valproate among women of childbearing age (18-44 years of age) and
the risks valproate poses for a child through maternal exposure. The study population came from
the 2016-2018 MarketScan® Commercial dataset obtained by the Medical University of South
Carolina. In total, there were n=877 women aged 18-44 years of age. There were n=318 women
with greater than 3 months prescribed valproate, and there were n=149 women based on 6 month
pre-index insurance and 12 months post-index insurance where the data index was the date from
which the first valproate prescription was filled. This led to a final cohort size of 149 women.
The data was analyzed using measures of central tendency. Tests for differences between those
on birth control and those not on birth control were made using Student’s t-test for normally
distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chi-squared
tests for categorical data. Results include 14.5% of the original population being prescribed
valproate for 3 or more months, 33.6% being for migraines, followed by 31.5% for bipolar
disorder despite research being conducted primarily for those with epilepsy.
In conclusion, the research shows the need for further education on the risks of valproate
and women of childbearing age. This is based on the lack of studies focusing on the risks and
prescribing patterns outside of the epilepsy community. The research limitations included the
length and type of contraceptive use, which the study could not account for as only measurable
pregnancy prevention methods were studied. Future research could explore different funding
streams as our research focused on commercial payor billing data, which garnered a small
sample size.
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CHAPTER 1
INTRODUCTION
Background
Valproate, classified as an anticonvulsant or antiepileptic drug (AED), has several
modalities. The pharmaceutical is available as an extended-release formulation in capsule form,
as a delayed-release formulation in tablet form, a sprinkle capsule, or syrup (AHFS, 2020).
Valproate was first introduced for human use in 1967 in Europe, and its use was licensed in the
United Kingdom in 1975. It was not until 1978 that it became clinically available in the United
States as an immediate-release formulation and then again in 1983 as alternative formulations
(Adab et al., 2004).
The U.S. Food and Drug Administration (FDA) initially approved valproate to treat
seizures, but some valproate products are also approved to treat other ailments. Valproate is
widely popular for its broad range of anticonvulsant effects and that it also has limited sedative
and behavioral outcomes compared to other AEDs (Alsdorf & Wyszynski, 2005). Additionally,
it is recognized as one of the most critical AEDs for its wide spectrum effectiveness and is most
notable in the acute treatment of bipolar disorder (Alsdorf & Wyszynski, 2005). Valproate
products include valproate sodium, divalproex sodium, valproic acid, and other generics (FDA,
2015). As a result, the term valproate was be used to encompass the numerous varieties of the
drug.
Valproate entered the market as a therapeutic intervention for absence seizures. Since
then, its use has expanded to include the treatment of complex and partial seizures, as well as a
preventative for migraines in some countries, a treatment for acute mania, and as a mood
stabilizer for bipolar disorder (Macfarlane & Greenhalgh, 2018; Wyszynski et al., 2005).
Similarly, in 2012, about 1.5 million individuals received valproate on an outpatient basis, to
1

include 67% for psychiatric and mood disorders, 9% for migraines, and 9% for epilepsy in the
United States (Angus-Leppan & Liu, 2018).
Furthermore, valproate is said to cross the placenta and present a higher concentration in
the child than in the mother (Alsdorf & Wyszynski, 2005). Additionally, valproate is known to
induce apoptosis, a programmed cell death typically occurring in early development to eliminate
unwanted cells (NIH, n.d.; Velez-Ruiz & Meador, 2015). Furthermore, valproate is associated
with a significant risk increase for teratogenesis, production of malformations in a child,
compared to the baseline population rates and other ordinary AEDs for over 30 years of clinical
studies (Gerard & Meador, 2015; Jentink et al., 2010).
In a 1983 Morbidity and Mortality Weekly Report from the CDC, valproate was stated to
be a new cause of congenital malformations (CDC, 1983). The report found a significant
association between valproate exposure during the first trimester of pregnancy and spina bifida
and concluded that valproate should be considered a human teratogen (CDC, 1983). Since then,
many factors are said to contribute to the teratogenic properties. Some of these factors include
drug dosage, gestational age of the child at the time of the exposure, and differences in
metabolism between the mother and child (Alsdorf & Wyszynski, 2005).
Valproate's teratogenic properties have since been evidenced by clinical studies such as
those done by Weston et al. (2016), Christensen et al. (2013), and Eriksson et al. (2005). In
addition, national and international pregnancy registries have increasingly identified AEDs'
teratogenic properties (Alsdorf & Wyszynski, 2005; Tomson et al., 2011). Furthermore, across
several of these human studies, valproate has been the most highly associated with cognitive and
behavioral teratogenesis of all AEDs (Gerard & Meador, 2015). In the end, clinical research has
identified many risks associated with the drug that include those congenital malformations,
2

developmental delays, reduced cognitive function, and, most recently, autism (Roullet et al.,
2013).
Notably, animal studies have shown that the timing of exposure affects the type of
identified malformations. For example, valproate exposure during the first trimester of gestation
results in malformations of major organs. By contrast, exposure later in pregnancy results in an
increased risk of neurodevelopmental defects when brain cells proliferate and migrate (Alsdorf &
Wyszynski, 2005). Animal studies examining valproate have recently shown autistic-like
outcomes, including social behavior deficits, increased repetitive behaviors, and communication
deficits (Roullet et al., 2013).
Today, an increasing number of pregnant women continue to be exposed to valproate,
despite its use during the first trimester being associated with an increased risk of spina bifida
(Jentink et al., 2010; Koren, 2006). Adab et al. (2001) say that roughly one-third of all people
receiving AEDs were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was
exposed to AEDs whereby over one million women with epilepsy in the United States were of
childbearing age, and three to five births per 1,000 were to those women in 2015 (Adab et al.,
2001). Additionally, it was estimated that 1.5 million individuals were prescribed valproate, in
2012 and roughly 22% of those were women of childbearing age (Angus-Leppan. & Liu, 2018).
The total number of children exposed to AEDs, including valproate, however, is likely to be
more noteworthy due to their use as treatments for other conditions (Velez-Ruiz & Meador,
2015).
Not long after valproate was introduced for clinical use in epilepsy, emerging cases
suggested those increased risk of neural tube defects, including spina bifida (Koren et al., 2006;
Jentink et al., 2010). Today, although risk estimations associated with valproate vary, there may
3

be as much as a two- to three-fold risk increase in congenital malformations among babies born
to women with epilepsy on valproate compared to the general population (Adab et al., 2001).
Jentink et al. (2010) found in their review of published cohort studies that there were 14
significant malformations more commonly associated with valproate through various
antiepileptic databases. There was a major congenital malformation observed in 118 of 1,565
pregnancies. For these malformations, the risk appeared to be significantly higher with the
association of exposure to valproate during the first trimester of pregnancy compared to those
with no exposure to antiepileptic drugs during the first trimester (Jentink et al., 2010).
The researchers found significant associations between exposure to valproate
monotherapy in the first trimester in six conditions: spina bifida, cleft palate, atrial septal defect,
hypospadias, polydactyly, and craniosynostosis. In addition, the researchers found that the risks
for five of the conditions were two to seven times higher for exposed children. Specifically, the
risk for spina bifida was as much as 16 times higher for exposed children depending on the
control group used. Researchers also found an association between limb defects and exposure to
valproate compared to other drugs used as an antiepileptic (Jentink et al., 2010).
In 1984, Fetal Valproate Syndrome first started being used to describe the prominent
malformations observed in children exposed to valproate in utero. This term refers to a collection
of minor and major malformations occurring in exposed children, often consisting of facial
malformations, including a flat nasal bridge, small upturned nose, and thin upper lip, as well as
multiple major malformations and central nervous system dysfunctions (Wyszynski et al., 2005).
Additionally, valproate also causes severe malformations that primarily affect the brain
and spinal cord, causing lower intelligence and other cognitive malformations. The low
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intellectual ability is seen in 30% to 40% of children born to mothers who took valproate (AHFS,
2020; Sawhney et al., 2019). This exposure to valproate affects a child's development during
pregnancy with a significant IQ reduction compared to children exposed to other AEDs. The IQ
reductions (8-11 points lower) are considered substantial enough to affect their education and
affect them later in life when entering the workforce (Tomson et al., 2015). Children exposed to
valproate in utero have a delay in achieving developmental milestones, particularly verbal skills.
This delay includes communication problems, including talking, poor language skills.
Additionally, valproate also can cause coordination problems, including walking and learning
problems affecting memory, emotions, and behavior (AHFS, 2020; Gerard & Meador, 2015;
Sawhney et al., 2019).
Recently it has been found that children exposed to valproate are more likely to
demonstrate poor adaptive skills and a heightened risk for neurodevelopmental disorders,
including attention deficit hyperactivity disorder and autism (Gerard & Meador, 2015). Evidence
supports this link between cognitive function and the increased risk of autism with valproate
exposure (Roullet et al., 2013).
Of all the AEDs available, the use of valproate during childbearing years and pregnancy
has raised the most notable concerns (Roullet et al., 2013). FDA warnings related to valproate
during pregnancy have emphasized the need for reassessment in its use clinically during these
years (Roullet et al., 2013). Hence, despite its known risks, valproate continues to be used in
women of childbearing age as several pregnancy registries have established the commonality of
valproate to be prescribed (Roullet et al., 2013). Subsequently, valproate has clinical guidelines
for practitioners that suggest that it should be avoided during pregnancy. These guidelines
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indicate that valproate should be avoided in pregnancy if possible due to the increased risks of
congenital malformations (Werler et al., 2011).
This project intends to inform professional practice regarding the number of prescriptions
for valproate prescribed to women of childbearing age. Additionally, it looks at how many of
those women of childbearing are on pregnancy preventive programs or have a pregnancy given
the fetal risks associated with valproate. This research is valuable as a consulting report to
physician specialties such as psychiatry, neurology, and obstetrics.
Aim
To examine the number of women of childbearing age (18-44) who are prescribed valproate,
some of their outcomes, and rates of pregnancy prevention to avoid risks as a result of prenatal
valproate exposure.
Under this aim, this project intends to answer the following research questions:
•

Question 1: At what rate is valproate being prescribed to women of childbearing age?

•

Question 2: What are the most common diagnoses (e.g., bipolar, epilepsy, migraines).

•

Question 3: For what age group of women is valproate most commonly prescribed?

•

Question 4: How many of those women prescribed valproate were part of a pregnancy
prevention program?

•

Question 5: Of those women taking valproate, how many later experienced a pregnancy?

Study Importance
As the risks to children of mothers exposed to AEDs have been increasingly understood,
the warnings against such medications have been strengthened. Specifically, there has been an
increase in healthcare professionals and available patient resources regarding the acceptable use
6

of valproate (Sawhney et al., 2019). Worldwide there is an agreement that valproate is a serious
teratogen. However, there is still no agreement on proper guidelines for women who may
become pregnant (Angus-Leppan, & Liu, 2018).
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CHAPTER II
LITERATURE REVIEW
Introduction
Until recently, there were very little data on the effects of antiepileptic drug (AED)
exposure in utero. However, in the past two decades, data from several prospective pregnancy
registries have significantly increased the understanding of the critical risks for major congenital
malformations associated with several AEDs (Gerard & Meador, 2015). This chapter examines
the risks associated with valproate among women of childbearing age and the risks valproate
poses for a child through maternal exposure. The chapter primarily looks at valproate in the
context of its therapeutic use for epilepsy, as research into its teratogenic properties is limited
outside of this field.
Valproate as a Therapeutic
Valproate, classified as an anticonvulsant or AED, has several modalities. The
pharmaceutical is available as an extended-release formulation in capsule form, as a delayedrelease formulation in tablet form, a sprinkle capsule, or syrup (AHFS, 2020). Valproate was first
introduced for human use in 1967 in Europe, and its use was licensed in the United Kingdom in
1975. It was not until 1978 that it became clinically available in the United States as an
immediate-release formulation and then again in 1983 as alternative formulations (Adab et al.,
2004).
The U.S. Food and Drug Administration (FDA) initially approved valproate to treat
seizures, but some valproate products are also approved to treat other ailments. Valproate is
widely popular for its broad range of anticonvulsant effects and that it also has limited sedative
and behavioral outcomes compared to other AEDs (Alsdorf & Wyszynski, 2005). Additionally,
8

it is recognized as one of the most critical AEDs for its wide spectrum effectiveness and is most
notable in the acute treatment of bipolar disorder (Alsdorf & Wyszynski, 2005). Valproate
products include valproate sodium, divalproex sodium, valproic acid, and other generics (FDA,
2015). As a result, the term valproate was used to encompass the numerous varieties of the drug.
Valproate is a y-aminobutyric acid (GABA) agonist (Angus-Leppan & Liu, 2018;
Wyszynski et al., 2005). Studies show enhanced GABA inhibition and the blockade of NMDA
receptors impairs neurogenesis and cell migration, which in turn can lead to cortical dysplasia
and reduced brain volume (Velez-Ruiz & Meador, 2015). Furthermore, valproate targets
neurotransmitters, ion channels, and second messenger systems in the brain. This
neurotransmitter medium in a developing brain plays a significant role in regulating neuronal
differentiation and migration (Velez-Ruiz & Meador, 2015).
Drug Uses
Valproate entered the market as a therapeutic intervention for absence seizures. Since
then, its use has expanded to include the treatment of complex and partial seizures, as well as a
preventative for migraines in some countries, a treatment for acute mania, and as a mood
stabilizer for bipolar disorder (Macfarlane & Greenhalgh, 2018; Wyszynski et al., 2005).
Similarly, in 2012, about 1.5 million individuals received valproate on an outpatient basis, to
include 67% for psychiatric and mood disorders, 9% for migraines, and 9% for epilepsy in the
United States (Angus-Leppan & Liu, 2018).
According to Macfarlane and Greenhalgh (2018), the drug's use for epilepsy continues to
decline in the United Kingdom as the number of third-generation anticonvulsants increase; its
use for bipolar disorder has been growing. Furthermore, this happens mostly among many
childbearing age women, which already make up a significant portion of recipients. These data
9

were like those also seen in Ireland. More alarming, 20% of pregnant women with epilepsy were
treated with valproate between 1999 to 2004. Subsequently, a more recent U.K. study revealed
that valproate constituted 25% of all AED prescriptions in pregnancy (Macfarlane &
Greenhalgh, 2018).
Valproate Transmission
Valproate is said to cross the placenta and present a higher concentration in the child than
in the mother (Alsdorf & Wyszynski, 2005). Consequently, valproate is known to induce
apoptosis, a programmed cell death typically occurring in early development to eliminate
unwanted cells (NIH, n.d.; Velez-Ruiz & Meador, 2015).
Teratogenic Properties
Valproate is associated with a significant risk increase for teratogenesis, production of
malformations in a child, compared to the baseline population rates and other ordinary AEDs for
over 30 years of clinical studies (Gerard & Meador, 2015; Jentink et al., 2010). In a 1983
Morbidity and Mortality Weekly Report from the CDC, valproate was stated to be a new cause of
congenital malformations (CDC, 1983). The report found a significant association between
valproate exposure during the first trimester of pregnancy and spina bifida and concluded that
valproate should be considered a human teratogen (CDC, 1983). Since then, many factors are
said to contribute to the teratogenic properties. Some of these factors include drug dosage,
gestational age of the child at the time of the exposure, and differences in metabolism between
the mother and child (Alsdorf & Wyszynski, 2005).
Valproate's teratogenic properties have since been evidenced by clinical studies such as
those done by Weston et al. (2016), Christensen et al. (2013), and Eriksson et al. (2005). In
addition, national and international pregnancy registries have increasingly identified AEDs'
10

teratogenic properties (Alsdorf & Wyszynski, 2005; Tomson et al., 2011). Furthermore, across
several of these human studies, valproate has been the most highly associated with cognitive and
behavioral teratogenesis of all AEDs (Gerard & Meador, 2015). In the end, clinical research has
identified many risks associated with the drug that include those congenital malformations,
developmental delays, reduced cognitive function, and, most recently, autism (Roullet et al.,
2013).
Dose-Dependent Risks
Although it can be considered generally unsafe for mothers and their developing fetuses,
valproate has dose-dependent teratogenic risks (Virta et al., 2018). Although risks are still
prevalent, most studies suggest that the chances for major congenital malformations begin to
increase significantly at doses of 600 mg a day and become more prominent at doses above
1,000 mg per day (Koren et al., 2006). Many researchers agree that valproate use creates an
increased risk for those significant congenital malformations, especially in doses over 1,000 mg
per day (Alsdorf & Wyszynski, 2005). Furthermore, apoptosis inducement, as previously
discussed, begins to occur at levels below the therapeutic range (Velez-Ruiz & Meador, 2015).
The standard therapeutic valproate doses range from 200 mg to 3,600 mg per day (Roullet et al.,
2013).
Additionally, a study by Tomson et al. (2011) examined significant congenital
malformations of children up to 1 year in age. These data came from the EURAP pregnancy
registry and focused on children exposed to four of the most common AEDs, one of which was
valproate. The authors aimed to establish the risks of major congenital malformations after
monotherapy exposure. This study showed that dose contributed to the risk of congenital
disabilities. Analysis showed that an increased dose of valproate was associated with an
11

increased incidence of congenital malformations. The researchers assessed the pregnancy
outcomes according to the dose taken at the time of conception, despite any subsequent dose
changes (Tomson et al., 2011).
Subsequently, Mawhinney et al. (2012) used the U.K. Epilepsy and Pregnancy Register
to extract data for those pregnancies that were exposed to valproate. They calculated
malformation rates and relative risks as a function of the valproate exposure focusing on all
pregnancies exposed solely to valproate during the first trimester (Mawhinney et al., 2012). They
found a significant dose-response with an almost doubling of the risk for those exposed to more
than 1000 mg a day compared to those on less than 1000 mg a day (Mawhinney et al., 2012).
Moreover, a retrospective study of children born to mothers with epilepsy found that
doses above 800 mg were associated with 8-15-point lower verbal IQ Valproate exposure was
associated with additional education needs (AEN), as 19.7% of the sample had received speech
therapy at some point (Adab et al., 2004). Further, Gedzelman & Meador (2012) found that
valproate exposure also appears to have a dose-dependent IQ impact, with the effects being more
significant on verbal than non-verbal IQ abilities (Gedzelman & Meador, 2012).
Polytherapy Versus Monotherapy
In addition to dose, valproate is also used as either a form of monotherapy or
polytherapy, meaning two or more treatments. Research shows that children with prenatal
polytherapy exposure have worse cognitive and behavioral outcomes versus those children
exposed to monotherapy or unexposed to valproate, whereby there is an increased risk of defects
of neurodevelopment when used as a form of polytherapy (Roullet et al., 2013; Velez-Ruiz &
Meador, 2015).
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In a preliminary retrospective study by Adab et al. (2001), a comparison was drawn
between the proportion of school-age children exposed to different drug regimens and those who
had AENs with or without physical disability born to mothers with epilepsy. They found that
exposure to polytherapy, including valproate, was highly associated with AENs compared to
both those who were unexposed and those who were exposed to polytherapy excluding valproate
(Adab et al., 2001).
Adab et al. (2001) found that one of the most common monotherapy exposures (37.3%)
for school-age children was valproate in utero. The polytherapy regimens often vary, but
valproate combined with another AED is one of the most common polytherapy forms. Of the
women taking AEDs at the time of pregnancy, over two-thirds were on monotherapy, and most
of those were on valproate (Adab et al., 2001). Additionally, data for specific drug regimens
showed that much of the risks for AENs among those exposed to monotherapy or polytherapy
might be accounted for by valproate exposure. Thirty percent of those exposed to valproate
monotherapy in utero had AENs, compared to 3.2% and 6.5% of those exposed to other AEDs
studied (Adab et al., 2001).
Rodent Studies
Behavioral studies of mice and rat offspring are the most used model in human disease
research to provide insight into the mechanisms underlying many diseases. They are used to
explore the efficacy of drugs and predict patient responses (Justice, 2016). There are reports of
valproate teratogenicity in animals since the 1970s and in humans since the 1980s, whereby
mouse and rat animal studies have examined anatomical, behavioral, molecular, and
physiological outcomes of in utero exposure to valproate (Angus-Leppan & Liu, 2018; Roullet et
al., 2013).
13

Notably, these animal studies have shown that the timing of exposure affects the type of
identified malformations. For example, valproate exposure during the first trimester of gestation
results in malformations of major organs. By contrast, exposure later in pregnancy results in an
increased risk of neurodevelopmental defects when brain cells proliferate and migrate (Alsdorf &
Wyszynski, 2005). Additionally, animal studies examining valproate have recently shown
autistic-like outcomes, including social behavior deficits, increased repetitive behaviors, and
communication deficits (Roullet et al., 2013).
Furthermore, animal studies have suggested that AED-induced apoptosis alters the
neurotransmitter environment while impairing synaptogenesis, or the formation of synapses in
the nervous system. Moreover, impaired synaptogenesis is one of the mechanisms responsible
for cognitive and behavioral teratogenesis (Velez-Ruiz & Meador, 2015).
Valproate and Pregnancy
Today, an increasing number of pregnant women continue to be exposed to valproate,
despite its use during the first trimester being associated with an increased risk of spina bifida
(Jentink et al., 2010; Koren, 2006). Adab et al. (2001) say that roughly one-third of all people
receiving AEDs were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was
exposed to AEDs whereby over one million women with epilepsy in the United States were of
childbearing age, and three to five births per 1,000 were to those women in 2015 (Adab et al.,
2001). Velez-Ruiz & Meador, 2015). Additionally, it was estimated that 1.5 million individuals
were prescribed valproate, in 2012 and roughly 22% of those were women of childbearing age
(Angus-Leppan. & Liu, 2018). The total number of children exposed to AEDs, including
valproate, however, is likely to be more noteworthy due to their use as treatments for other
conditions (Velez-Ruiz & Meador, 2015).
14

Identification of the Risks Associated with Valproate Exposure
Not long after valproate was introduced for clinical use in epilepsy, emerging cases
suggested those increased risk of neural tube defects, including spina bifida (Koren et al., 2006;
Jentink et al., 2010). Today, although risk estimations associated with valproate vary, there may
be as much as a two- to three-fold risk increase in congenital malformations among babies born
to women with epilepsy on valproate compared to the general population (Adab et al., 2001).
To determine the risks of major congenital malformations for children exposed to AEDs
in utero, the U.K. Epilepsy and Pregnancy Register was established (Mawhinney et al., 2012).
According to the organization's website, the register began in 1996 for mothers who take one or
more AED to prevent seizures. The organization's main objective is to obtain information on the
occurrence of significant malformations they then publish. Furthermore, to identify the risks
posed by valproate and other AEDs, the EURAP Epilepsy and Pregnancy Registry is an
observational cohort study representing physicians from 45 countries, including Europe, Asia,
Latin America, and Africa. According to the most recent figures, this registry was established in
1999 and had more than 700 collaborators (EURAP, 2018; Tomson et al., 2011).
Structural Malformations
Valproate has been associated with a number of structural malformations in developing
children, including Spina Bifida. A 1982 study established a 20-fold increase in the risk for the
occurrence of spina bifida associated with valproate during pregnancy (Wyszynski et al., 2005).
A communicative Morbidity and Mortality Weekly Report by the CDC (1983) found that two
were exposed to valproate among 118 infants with spina bifida. In a group of other
malformations, three infants were exposed to valproate. At that time, the CDC estimated that a
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pregnant woman in the United States, treated with valproate, would have a 1-2% chance of
having a child with spina bifida (CDC, 1983).
To add further evidence of the drug's teratogenicity, the Morbidity and Mortality Weekly
Report (1983) also referenced a U.K. researcher who concluded that, of infants born to 196
women treated with valproate, nine had spina bifida, and 30 had other structural defects that
included cardiovascular defects, orofacial clefts, and abnormalities of the fingers or toes (CDC,
1983). Despite these previous reports, as of 2001, only neural tube defects were explicitly linked
with valproate, which had the risk for spina bifida as high as 5% (Adab, Jacoby, Smith, &
Chadwick, 2001; Wyszynski et al., 2005).
Likewise, a prospective study looked at the rate of significant malformations identified at
birth from mothers who had taken valproate during pregnancy and were enrolled in the North
American Antiepileptic Drug Pregnancy Registry, a surveillance registry system for pregnant
women exposed to anticonvulsant drugs. For this study, medical records were obtained regarding
the mother's medical history and any malformations identified in the child (Wyszynski et al.,
2005). The researchers studied 3,441 women enrolled in the pregnancy registry between
February 1, 1997, and November 20, 2003. Valproate was taken by 235 of those women for
epileptic seizures. In children from this exposed group of women, 16 infants were confirmed as
having significant malformations—a four-fold increase in risk for the women taking valproate
over other drugs (Wyszynski et al., 2005).
Additionally, Koren et al. (2006) selected controlled cohort studies searching several
databases that reported valproate use during the first trimester of pregnancy. They selected
studies that had comparison groups of women treated with other antiepileptic drugs, untreated
epileptic women, or healthy women that could represent the general population of pregnant
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women. After reviewing more than 1,700 exposed infants reported throughout 11 cohort studies,
researchers found that women who took valproate during the time in which the embryo develops
had more than 2.5 times the risk of having a child with malformations above other AEDs. They
also found that using valproate during pregnancy was shown to have a three-fold increase in
major congenital malformations compared to the general population not exposed to AEDs
(Koren et al., 2006).
Furthermore, Jentink et al. (2010) found in their review of published cohort studies that
there were 14 significant malformations more commonly associated with valproate through
various antiepileptic databases. There was a major congenital malformation observed in 118 of
1,565 pregnancies. For these malformations, the risk appeared to be significantly higher with the
association of exposure to valproate during the first trimester of pregnancy compared to those
with no exposure to antiepileptic drugs during the first trimester (Jentink et al., 2010). The
researchers then tested this information in a large population-based case-control study. They
found significant associations between exposure to valproate monotherapy in the first trimester
in six conditions: spina bifida, atrial septal defect, cleft palate, hypospadias, polydactyly, and
craniosynostosis. They found that the risks for five of the conditions were two to seven times
higher for exposed children. Specifically, the risk for spina bifida was as much as 16 times
higher for exposed children depending on the control group used. Researchers also found an
association between limb defects and exposure to valproate compared to other drugs used as an
antiepileptic (Jentink et al., 2010).
Later, Werler et al. (2011) evaluated the use of specific antiepileptic drugs in pregnancy
and their relationship with congenital malformations. They used data from the National Birth
Defects Prevention Study, one of the largest studies on birth defects in the United States. They
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assessed the use of these drugs and the risks posed for neural tube defects, oral clefts, heart
defects, hypospadias, a defect in male genitals, and other significant congenital disabilities
(CDC, 2019a; Werler et al., 2011). The authors found that increased risks that were drug-specific
were observed for valproate. These risks were associated with neural tube defects, oral clefts,
heart defects, and hypospadias. For example, mothers exposed to valproate were 9.7 times more
likely to have a child with a neural tube defect, 4.4 times more likely to have a child with an oral
cleft, 2.0 times more likely to have a heart defect, and 2.4 times more likely to have hypospadias
(Werler et al., 2011).
Lastly, Weston et al. (2016) assessed the effects of prenatal exposure to AEDs on the
prevalence of congenital malformations using several sources, including the Cochrane Epilepsy
Group Specialized Register and Medline. Prospective cohort studies, cohort studies set within
pregnancy registries, and randomized controlled trials were used. Fifty studies were included,
with 31 contributing to the meta-analysis (Weston et al., 2016). The researchers found that
children exposed to valproate had the highest malformation risk levels than other AED. Children
exposed to valproate also had a higher risk than both groups of children in the control group
versus children exposed to the other AEDs whereby the level of malformation risk was linked to
the amount or dose of valproate that the child was exposed to in utero (Weston et al., 2016).
Fetal Valproate Syndrome
In 1984, Fetal Valproate Syndrome first started being used to describe the prominent
malformations observed in children exposed to valproate in utero. This term refers to a collection
of minor and major malformations occurring in exposed children, often consisting of facial
malformations, including a flat nasal bridge, small upturned nose, and thin upper lip, as well as
multiple major malformations and central nervous system dysfunctions (Wyszynski et al., 2005).
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Moreover, no test can confirm a diagnosis of Fetal Valproate Syndrome. Other possible causes of
the signs and symptomology must be ruled out first. However, Fetal Valproate Syndrome is often
suspected in an infant with one or more of the signs and symptoms associated should the mother
report having taken valproate during pregnancy (NIH, 2017).
Treatment for Fetal Valproate Syndrome is based on the signs and symptoms present in
each child as management often involves a team of medical specialists (NIH, 2017). Moreover,
parents of children born with Fetal Valproate Syndrome express grief and anger over delays in
recognizing the problem, delays in diagnosis, and inadequate support for those with lifelong
disabilities (Angus-Leppan, & Liu, 2018).
Cognitive Malformations
Valproate also causes severe malformations that primarily affect the brain and spinal
cord, causing lower intelligence and other cognitive malformations. The low intellectual ability
is seen in 30% to 40% of children born to mothers who took valproate (AHFS, 2020; Sawhney et
al., 2019).
IQ Reductions
Exposure to valproate affects a child's development during pregnancy with a significant
IQ reduction compared to children exposed to other AEDs. The IQ reductions (8-11 points
lower) are considered substantial enough to affect their education and affect them later in life
when entering the workforce (Tomson et al., 2015).
A meta-analysis of three studies, composed of 67 children exposed to the drug, calculated
that fetal valproate exposure was associated with a six-point decrease in full-scale IQ (Gerard &
Meador, 2015). Additionally, in a study by Eriksson et al. (2005), the neurological and cognitive
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functions of school-aged children aged six and below exposed to valproate in utero were
examined through a population-based, controlled study that consisted of 28 children. They found
that low intelligence prevalence with valproate exposure was 19%, while exceptionally low
intelligence was 10% in the valproate exposed children (Eriksson et al., 2005).
Furthermore, an FDA Drug Safety Communication (2011) warned the public that a
mother's valproate use during pregnancy heightens her risk of having children born with lowered
cognitive test scores. Furthermore, the Drug Safety Communication (2011) outlined initial
cognitive test scores performed on children at age 3 with supportive studies of cognitive tests
performed on children ages 5 to 16, with the most extensive research being a prospective cohort
study conducted in the United States and the United Kingdom. However, the communication
concluded that the long-term effects and whether the impact on cognitive development occurs
when the child's exposure does not span the entirety of pregnancy are unknown (FDA, 2011).
Developmental Delays
Children exposed to valproate in utero have a delay in achieving developmental
milestones, particularly verbal skills. This delay includes communication problems, including
talking, poor language skills. Additionally, valproate also can cause coordination problems,
including walking and learning problems affecting memory, emotions, and behavior (AHFS,
2020; Gerard & Meador, 2015; Sawhney et al., 2019).
To study the cognitive effects of valproate, Meador et al. (2009) used a cohort consisting
of 258 children, 53 of which were exposed to valproate. As part of the Neurodevelopmental
Effects of Antiepileptic Drugs study enrolling pregnant women who used AEDs from October
1999 through February 2004 in 25 epilepsy centers in the United States and the United Kingdom,
Researchers found the poorest cognitive outcomes for children exposed to valproate. This
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included increased developmental delays in children younger than 6 years of age, increased
special education needs in children 5 to 18 years of age, and reduced verbal IQ in children 6 to
16 years of age, compared to unexposed children (Meador et al., 2009).
Autism
Recently it has been found that children exposed to valproate are more likely to
demonstrate poor adaptive skills and a heightened risk for neurodevelopmental disorders,
including attention deficit hyperactivity disorder and autism (Gerard & Meador, 2015). Evidence
supports this link between cognitive function and the increased risk of autism with valproate
exposure, thereby stressing the importance of understanding how the drug impacts a child's
neurodevelopment (Roullet et al., 2013).
Clinical studies show valproate exposure in the first trimester of pregnancy is associated
with a higher child incidence of autism. This association is based initially on the increased
frequency of autistic symptoms of children diagnosed with Fetal Valproate Syndrome despite the
number of studies reporting the prevalence of autism following valproate exposure being limited
(Roullet et al., 2013). Supporting this, Christensen et al. (2013) conducted a population-based
cohort study evaluating the risk of autism in children exposed to valproate prenatally in
Denmark. They found a higher risk of autism spectrum disorder and childhood autism among
children of women who used valproate during pregnancy. The risks were also higher than those
for children whose mothers were previously valproate users but stopped at least 30 days before
conception (Christensen et al., 2013).
History of Guidelines
Of all the AEDs available, the use of valproate during childbearing years and pregnancy
has raised the most notable concerns (Roullet et al., 2013). FDA warnings related to valproate
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during pregnancy have emphasized the need for reassessment in its use clinically during these
years (Roullet et al., 2013). Hence, despite its known risks, valproate continues to be used in
women of childbearing age as several pregnancy registries have established the commonality of
valproate to be prescribed (Roullet et al., 2013). Subsequently, valproate has clinical guidelines
for practitioners that suggest that it should be avoided during pregnancy. These guidelines
indicate that valproate should be avoided in pregnancy if possible due to the increased risks of
congenital malformations (Werler et al., 2011).
Supporting these claims, according to Jentink et al. (2010), the American Academy of
Neurology recommended that valproate also be avoided during pregnancy, if possible. However,
it might be challenging to avoid valproate provided reasonable seizure control (Jentink et al.,
2010). Additionally, building on those previous dose-dependence claims, doses of more than
1,000 mg per day should be avoided entirely when there is a likelihood of pregnancy (Mawer et
al., 2002).
Moreover, the FDA warned that women of childbearing age deciding to take valproate
should use adequate birth control precautions while taking the medications. The FDA also
advised healthcare professionals to inform women of childbearing age of the increased risks
associated with this drug. They should also continue to counsel women that valproate carries an
increased risk of major malformations when used during pregnancy (FDA, 2011).
More recently, the FDA released a drug safety communication advising healthcare
professionals and women that pregnant women should not take valproate to prevent migraine
headaches. This was based on recent studies that suggest that these medications can cause
decreased IQ scores in children whose mothers took the drugs while pregnant (FDA, 2013).
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Most recently, the AHFS Patient Medication Information in the United States concluded
that women of childbearing age not using effective birth control methods or pregnant women
must not take valproate for migraine headache prevention, and pregnant women should only take
valproate to treat seizures or bipolar disorder if other medications have not successfully
controlled the symptoms or other drugs cannot be used. If valproate is being used, one must use
effective birth control throughout treatment (AHFS, 2020).
Additionally, in the United Kingdom, a national alert was issued in 2018. The U.K.
Medicines and Healthcare Products Regulatory Agency advised that valproate was not
recommended in women of childbearing age unless other treatments have been ineffective at
managing the symptoms or cannot be tolerated. When alternatives are not possible, there should
also be a pregnancy prevention program in place. This strengthened regulation and included new
advisement for the use of valproate in pregnancy for bipolar disorder. The advisement is that,
should a woman with bipolar disorder become pregnant, the valproate treatment must be
discontinued or changed to a treatment alternative (Sawhney et al., 2019). This new guidance
required that practitioners be obligated to identify all women within their practice receiving
valproate and arrange a prompt review of their contraceptive measures. They were also required
to be referred to a specialist to have annual reviews (Sawhney et al., 2019).
Some additional imposed rulings addressing the defects are as follows (Angus-Leppan &
Liu, 2018; Macfarlane & Greenhalgh, 2018; Virta et al., 2018).
•

In 2014, the New Zealand Medicines and Medical Devices Safety Authority said that
valproate should not be used in women of childbearing potential unless other treatments
are ruled ineffective.
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•

In 2014, documented teratogenic effects of valproate prompted restrictions in Finland of
its use in females of childbearing age.

•

In 2016, the UK Royal College of Obstetricians and Gynecologists recommended
avoiding prescribing this drug to any childbearing age women.

•

In 2016, the United States' stance was that its use might be acceptable should other
medications not control the symptoms for which it is prescribed for epilepsy and bipolar.
The risk for pregnant women outweighs any possible benefit for migraines.

•

In 2017, the French National Agency for the Safety of Medicines and Health Products
(ANSM) imposed a nationwide ban against valproate in pregnancy due to the teratogenic
risks

•

In 2018. the European Medicines Agency's Pharmacovigilance Risk Assessment
Committee ruled that valproate must not be used in pregnancy unless there is a pregnancy
prevention program in place.
Finally, the FDA indicated that stronger warnings about its use during pregnancy would

be added to the drug labels and valproate's pregnancy category for migraine use would be
changed from a "D," meaning the potential benefit of the drug in pregnant women may be
acceptable despite the potential risks, to an "X," meaning that the risk of use in pregnant women
outweighs any possible benefit (FDA, 2013). This is concluding that for use in pregnant women
with epilepsy or bipolar, valproate should only be prescribed if other medications are not
effective in treating the condition or are otherwise unacceptable for their condition. However,
valproate products remain in the pregnancy category "D" for treating epilepsy and manic
episodes associated with bipolar disorder (FDA, 2013). Regarding women of childbearing age
who are not pregnant, valproate should not be taken for any condition unless the drug is essential
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to the management of the woman's medical condition. Non-pregnant women of childbearing age
should use effective birth control (FDA, 2013).
The Stance of Advocacy Groups
Consensus is growing to reduce the number of women taking valproate. This momentum
comes from patient support groups, healthcare professionals, and the media. Expert advisory
groups have limited responses, and regulations have varied. Reactions have ranged from those
advocating shared decision making and informed patient choice to barring the use in pregnancy
coupled with a pregnancy prevention program in those still taking the drug (Angus-Leppan, &
Liu, 2018). Advocacy groups have suggested that the government, industry, and medical
responses are too slow (Angus-Leppan, & Liu, 2018).
Some groups even propose a total ban on valproate as the only way to avoid future
problems. The fundamental assumption behind those who want the drug banned is that valproate
risks are so high for children that informed consent for the drug in pregnant women is not
sufficient. A complete ban on the use during pregnancy would imply that a pregnancy prevention
program is enforced with any woman of childbearing age who still wishes to take the drug. This
would include a negative pregnancy test before starting a treatment or as part of a regular review
process (Angus-Leppan, & Liu, 2018). Lastly, many advocacy groups feel that practitioners
should inform women of the increased risks of cognitive deficits associated with the use of
valproate, especially in early pregnancy, and when avoidable, the drug should not be used for
treatment in female patients of childbearing age (Koren et al., 2006; Tomson et al., 2015).
For instance, there are certain epilepsies where alternatives are either few or have been
deemed ineffective. In these scenarios, valproate would be appropriate to be prescribed to
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females of childbearing age. Discussions should be taken that evaluate the risk-benefit of
treatment options (Tomson et al., 2015).
Discussion of Previous Studies' Limitations
According to some researchers, previous studies' findings are limited by small samples of
exposed women and often a retrospective study design (Alsdorf & Wyszynski, 2005; Tomson et
al., 2011). However, limitations aside, extensive clinical research outlines the health risks
associated with in utero exposure to valproate (Roullet et al., 2013). The majority of research has
demonstrated a consistent association between valproate exposure and development delay, for
example (Gerard & Meador, 2015).
Conclusion
Due to the rapid introduction of new drugs, when and how the drugs are prescribed have
changed dramatically. There is a need to develop satisfactory methods to examine the risks of
both old and new AEDs as data suggests that valproate should not be used as a first-line
antiepileptic drug in women of childbearing age since data shows that roughly half of all
pregnancies are unplanned (Adab et al., 2001; CDC, 2019b, Meador, 2009).
As the risks to children of mothers exposed to AEDs have been increasingly understood,
the warnings against such medications have been strengthened. Specifically, there has been an
increase in healthcare professionals and available patient resources regarding the acceptable use
of valproate (Sawhney et al., 2019). Worldwide there is an agreement that valproate is a serious
teratogen. However, there is still no agreement on proper guidelines for women who may
become pregnant (Angus-Leppan, & Liu, 2018).
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Given the risk associated with exposure during pregnancy, many advocates feel that
valproate should be avoided, whenever possible, for epilepsy in women of childbearing age.
When valproate is the most appropriate for treatment, advocacy groups say that the patient
should be informed of the risks associated with valproate use during pregnancy, and all treatment
alternatives and effective contraception, when relevant, should be ensured for those prescribed
valproate (Sawhney, 2019). Furthermore, according to surveys in the United Kingdom, around
half of epileptic women are unaware that valproate poses any risks to the child (Angus-Leppan &
Liu, 2018; Macfarlane & Greenhalgh, 2018).
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CHAPTER III
METHODOLOGY
Specific Aims
This project intends to inform professional practice regarding the number of prescriptions
for valproate prescribed to women of childbearing age. Additionally, it looks at how many of
those women of childbearing are on pregnancy preventive programs or have a pregnancy given
the fetal risks associated with valproate. This research is valuable as a consulting report to
physician specialties such as psychiatry, neurology, and obstetrics.
Aim
To examine the number of women of childbearing age (18-44) who are prescribed valproate,
some of their outcomes, and rates of pregnancy prevention to avoid risks resulting from prenatal
valproate exposure.
Under this aim, this project intends to answer the following research questions:
•

Question 1: At what rate is valproate being prescribed to women of childbearing age?

•

Question 2: What are the most common diagnoses (e.g., bipolar, epilepsy, migraines).

•

Question 3: For what age group of women is valproate most commonly prescribed?

•

Question 4: How many of those women prescribed valproate were part of a pregnancy
prevention program?

•

Question 5: Of those women taking valproate, how many later experienced a pregnancy?

Study Design
This study is a retrospective cohort study, the researcher followed the sample overtime
through billing data using a billing ID, focusing on incidence rates based on the specified
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research questions as part of an epidemiological case study design. The research sets to prove no
causal relationship but merely describe the distribution between the defined variables.
Population and Sample
The study sample is women of childbearing age, 18 to 44 years of age, based on the CDC
indicator definition for reproductive health (CDC, 2015). Inclusion data includes women
between the ages of 18 and 44 and those with three or more months of valproate prescription
fills. Excluded women were those not between the ages of 18 and 44 and those who had less than
three (3) months of valproate prescribed to them.
•

At what rate is valproate being prescribed to women of childbearing age?

Mawhinney et al. (2012) excluded women from their study women who were missing data on
drug dose and administration. Since this study is not concerned with dosage, there was no
exclusion.
•

What are the most common prescribing diagnoses (e.g., bipolar, epilepsy, migraines)?

Inclusion criteria included the three-common diagnosis (bipolar, epilepsy, and migraines).
Exclusion criteria were women with those outside these diagnoses.
•

For what age group of women is valproate most prescribed?

•

How many of those women prescribed valproate were part of a pregnancy prevention
program?

Inclusion criteria included those women who have a billing code of Z30-Z30.9 within their
billing history. Exclusion criteria consisted of any women who do not have a billing code within
their billing data.

29

•

How many of those women prescribed valproate were not part of a pregnancy prevention
program?

Inclusion criteria included those women who did not have a billing code of Z30-Z30.9 within
their billing history. Exclusion criteria consisted of any women with the billing codes of Z30 to
Z30.9 billing code within their billing data.
•

Of those women taking valproate, how many went on to experience pregnancy?

Inclusion criteria included all pregnancies (Z33). Mawer et al. (2002) had no exclusions in their
study but instead included every pregnancy known by women attending the clinic. Since we are
not concerned with the viability of the pregnancies, all records were included. There were no
exclusions.
The study population comes from the 2016-2018 MarketScan® Commercial dataset
obtained by the Medical University of South Carolina. This dataset is a compiled set of 119
million privately insured individuals' billing records. The data are de-identified and examined by
the IRB at MUSC and deemed non-human subjects.
Database
According to the White Paper for IBM MarketScan Research Databases for Health
Services Researchers (2019),
The IBM MarketScan® Commercial Database consists of medical and drug data from
employers and health plans. It contains data for several million individuals annually,
encompassing employees, their spouses, and dependents covered by employer-sponsored
private health insurance in the United States. These include PPOs and exclusive provider
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organizations (EPOs), POS plans, indemnity plans, HMOs, and consumer-directed health
plans (CDHPs).
This data is of value to the research because, as the White Paper (2019) continues,
Medical claims are linked to outpatient prescription drug claims and person-level
enrollment information. The MarketScan Commercial Database may offer a distinct
advantage over other databases for research on medication use. As these data are primarily
sourced from employers, claims for mail-order prescriptions and specialty pharmacies are
also included.
Definition of Variables
The control variable is birth control, whether oral pills, intrauterine devices, transdermal
patches, or other identifiable methods. The researcher used the searchable ICD-10-CM grouping
code of Z30 through Z30.9 for contraceptive management.
In the study, the researcher followed a subset of women prescribed valproate using the
women's billing data looking for searchable valproate NDC groupings of 71930-057-12 (oral).
Additionally, the researcher used the searchable ICD 10 group billing code of Z33 for pregnancy,
the DSM code of Z37.x for delivery, and the ICD 10 codes for bipolar F31.9.x, epilepsy G40.x,
and migraines G43.x.
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Table 1. ICD-10-CM codes
Description

Codes

Contraception Management

Z30 – Z30.9

Pregnancy

Z32-Z32.3

Delivery Outcome (i.e. births)

Z37- Z37.9

Bipolar

F31.9

Epilepsy

G40

Migraine

G43

Table 2. Study NDCs
Description

Route

Codes

DIVALPROEX SODIUM

ORAL

0074-3826

DIVALPROEX SODIUM

ORAL

0074-6114

DIVALPROEX SODIUM

ORAL

0074-6212

DIVALPROEX SODIUM

ORAL

0074-6214

DIVALPROEX SODIUM

ORAL

0074-6215

DIVALPROEX SODIUM

ORAL

0074-7126

DIVALPROEX SODIUM

ORAL

0378-0472

DIVALPROEX SODIUM

ORAL

0378-0473

DIVALPROEX SODIUM

ORAL

0615-7949

DIVALPROEX SODIUM

ORAL

0615-7950

DIVALPROEX SODIUM

ORAL

0615-7956

DIVALPROEX SODIUM

ORAL

0615-8237
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DIVALPROEX SODIUM

ORAL

0615-8242

DIVALPROEX SODIUM

ORAL

0615-8326

DIVALPROEX SODIUM

ORAL

0615-8327

DIVALPROEX SODIUM

ORAL

0615-8328

DIVALPROEX SODIUM

ORAL

0615-8329

DIVALPROEX SODIUM

ORAL

0615-8330

DIVALPROEX SODIUM

ORAL

0781-2243

DIVALPROEX SODIUM

ORAL

0832-7122

DIVALPROEX SODIUM

ORAL

0832-7123

DIVALPROEX SODIUM

ORAL

0832-7124

DIVALPROEX SODIUM

ORAL

0904-6363

DIVALPROEX SODIUM

ORAL

0904-6364

DIVALPROEX SODIUM

ORAL

0904-6615

DIVALPROEX SODIUM

ORAL

0904-6860

DIVALPROEX SODIUM

ORAL

0904-6861

DIVALPROEX SODIUM

ORAL

10370-510

DIVALPROEX SODIUM

ORAL

10370-511

DIVALPROEX SODIUM

ORAL

16714-484

DIVALPROEX SODIUM

ORAL

16714-485

DIVALPROEX SODIUM

ORAL

17856-0109

DIVALPROEX SODIUM

ORAL

27241-115

DIVALPROEX SODIUM

ORAL

29300-138

DIVALPROEX SODIUM

ORAL

29300-139
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DIVALPROEX SODIUM

ORAL

29300-140

DIVALPROEX SODIUM

ORAL

43063-295

DIVALPROEX SODIUM

ORAL

43353-547

DIVALPROEX SODIUM

ORAL

48433-125

DIVALPROEX SODIUM

ORAL

48433-126

DIVALPROEX SODIUM

ORAL

50090-2007

DIVALPROEX SODIUM

ORAL

50090-3416

DIVALPROEX SODIUM

ORAL

50090-3616

DIVALPROEX SODIUM

ORAL

50090-4187

DIVALPROEX SODIUM

ORAL

50090-4409

DIVALPROEX SODIUM

ORAL

50090-4737

DIVALPROEX SODIUM

ORAL

50090-4861

DIVALPROEX SODIUM

ORAL

50268-258

DIVALPROEX SODIUM

ORAL

51079-766

DIVALPROEX SODIUM

ORAL

51079-767

DIVALPROEX SODIUM

ORAL

51655-365

DIVALPROEX SODIUM

ORAL

55111-529

DIVALPROEX SODIUM

ORAL

55111-530

DIVALPROEX SODIUM

ORAL

55111-531

DIVALPROEX SODIUM

ORAL

55111-532

DIVALPROEX SODIUM

ORAL

55111-533

DIVALPROEX SODIUM

ORAL

55111-534

DIVALPROEX SODIUM

ORAL

55154-4679
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DIVALPROEX SODIUM

ORAL

55154-4759

DIVALPROEX SODIUM

ORAL

55154-7145

DIVALPROEX SODIUM

ORAL

55154-7640

DIVALPROEX SODIUM

ORAL

57237-047

DIVALPROEX SODIUM

ORAL

57237-048

DIVALPROEX SODIUM

ORAL

57237-106

DIVALPROEX SODIUM

ORAL

58118-0040

DIVALPROEX SODIUM

ORAL

60687-211

VALPROIC ACID

ORAL

0121-0675

VALPROIC ACID

ORAL

0121-1350

VALPROIC ACID

ORAL

0121-4675

VALPROIC ACID

ORAL

0527-5250

VALPROIC ACID

ORAL

0591-4012

VALPROIC ACID

ORAL

0615-8205

VALPROIC ACID

ORAL

0832-0310

VALPROIC ACID

ORAL

17856-0675

VALPROIC ACID

ORAL

17856-4012

VALPROIC ACID

ORAL

42291-844

VALPROIC ACID

ORAL

43353-085

VALPROIC ACID

ORAL

43353-107

VALPROIC ACID

ORAL

43353-279
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VALPROIC ACID

ORAL

50383-792

VALPROIC ACID

ORAL

60429-246

VALPROIC ACID

ORAL

60432-621

VALPROIC ACID

ORAL

60687-262

VALPROIC ACID

ORAL

63629-7597

VALPROIC ACID

ORAL

63739-253

VALPROIC ACID

ORAL

67046-807

VALPROIC ACID

ORAL

67046-808

VALPROIC ACID

ORAL

68094-193

VALPROIC ACID

ORAL

68094-701

VALPROIC ACID

ORAL

69452-150

VALPROIC ACID

ORAL

70518-0079

VALPROIC ACID

ORAL

70518-1968

VALPROIC ACID

ORAL

70518-2215

VALPROIC ACID

ORAL

71930-057

VALPROIC ACID

ORAL

72189-010
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Figure 1. Study Flowchart
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Data Analysis
These data were analyzed using SAS version 9.4 (Cary, NC). Data is described using
measures of central tendency (mean, median, mode) and dispersion (standard deviation,
quartiles, min, max). The researcher seeks to describe and quantify the number of pregnancies in
the dataset among women 18-44 years of age on valproate in this descriptive survey. Differences
between those on birth control and those not on birth control were made using student’s t-test for
normally distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chisquared tests for categorical data. Statistical significance has been defined a priori to be <0.05.
Limitations
Factors that affected my findings included the length of contraceptive use and type of
contraceptive use, such as condom use, which the study could not account for. The researcher
studied only measurable pregnancy preventions (oral pills, intrauterine devices, transdermal
patches) for this research. Filtering this data did not increase the level of control for these
factors. Additional limitations include the fact that there is no way to know whether a woman
prescribed valproate ingested the oral medication, nor does the researcher match dates to verify
events' timing.
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CHAPTER IV
ARTICLE MANUSCRIPT
Introduction
Valproate entered the market as a therapeutic intervention for absence seizures. Since
then, its use has expanded to include the treatment of complex and partial seizures, a
preventative for migraines in some countries, a treatment for acute mania, and a mood stabilizer
for bipolar disorder. 1,2 Today, an increasing number of pregnant women continue to be exposed
to valproate, despite its use during the first trimester being associated with an increased risk of
spina bifida. 3,4 Adab et al.5 say that roughly one-third of all people receiving Antiepileptic Drugs
(AEDs) were women of childbearing age in 2001. In addition, 1 in 250 pregnancies was exposed
to AEDs whereby, over one million women with epilepsy in the United States were of
childbearing age, and three to five births per 1,000 were to those women in 2015.5 Additionally,
it was estimated that 1.5 million individuals were prescribed valproate, in 2012 and roughly 22%
of those were women of childbearing age. 6 The total number of children exposed in utero to
AEDs, including valproate, however, is likely to be more noteworthy due to their use as
treatments for other conditions. 7
Valproate is associated with a higher risk for teratogenesis, the production of
malformations in a child, compared to the baseline population rates and other ordinary AEDs for
over 30 years of clinical studies. 8, 3 There are reports of valproate teratogenicity, the capability
to cause malformations, in animals since the 1970s. Additionally, teratogenicity has been
reported in humans since the 1980s, whereby mouse and rat animal studies have examined
anatomical, behavioral, molecular, and physiological outcomes of in utero exposure to valproate.
6, 9
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Notably, these animal studies have shown that the timing of exposure affects the type of
identified malformations. For example, valproate exposure during the first trimester of gestation
results in malformations of major organs. By contrast, exposure later in pregnancy results in an
increased risk of neurodevelopmental defects when brain cells proliferate and migrate. 10
Additionally, animal studies examining valproate have recently shown autistic-like outcomes,
including social behavior deficits, increased repetitive behaviors, and communication deficits. 9
Valproate's teratogenic properties have been evidenced by clinical studies done by
Weston 11, Christensen 12, and Eriksson 13. In addition, national and international pregnancy
registries have increasingly identified AEDs' teratogenic properties. 10, 14 Furthermore, across
several of these human studies, valproate has been the most highly associated with cognitive and
behavioral teratogenesis of all AEDs. 8 In the end, clinical research has identified many risks
associated with the drug that include those congenital malformations, developmental delays,
reduced cognitive function, and, most recently, autism. 9
A prospective study looked at the rate of significant malformations identified at birth
from mothers who had taken valproate during pregnancy and were enrolled in the North
American Antiepileptic Drug Pregnancy Registry, a surveillance registry system for pregnant
women exposed to anticonvulsant drugs. Medical records were obtained regarding the mother's
medical history and any malformations identified in the child for this study. 15 The researchers
studied 3,441women enrolled in the pregnancy registry between February 1, 1997, and
November 20, 2003. Valproate was taken by 235 of those women for epileptic seizures. In
children from this exposed group of women, 16 infants were confirmed as having significant
malformations—a four-fold increase in risk for the women taking valproate over other drugs. 15
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Additionally, Koren et al. 16 selected controlled cohort studies searching several
databases that reported valproate use during the first trimester of pregnancy. They selected
studies that had comparison groups of women treated with other antiepileptic drugs, untreated
epileptic women, or healthy women that could represent the general population of pregnant
women. After reviewing more than 1,700 exposed infants reported throughout 11 cohort studies,
researchers found that women who took valproate during the time in which the embryo develops
had more than 2.5 times the risk of having a child with malformations above other AEDs. They
also found that using valproate during pregnancy was shown to have a three-fold increase in
major congenital malformations compared to the general population not exposed to AEDs. 16
Furthermore, Jentink et al. 3 found in their review of published cohort studies that there
were 14 significant malformations more commonly associated with valproate through various
antiepileptic databases. There was a major congenital malformation observed in 118 of 1,565
pregnancies. For these malformations, the risk appeared to be significantly higher with the
association of exposure to valproate during the first trimester of pregnancy compared to those
with no exposure to antiepileptic drugs during the first trimester. 3 The researchers then tested
this information in a large population-based case-control study. They found significant
associations between exposure to valproate monotherapy in the first trimester in six conditions:
spina bifida, atrial septal defect, cleft palate, hypospadias, polydactyly, and craniosynostosis.
They found that the risks for five of the conditions were two to seven times higher for exposed
children. Specifically, the risk for spina bifida was as much as 16 times higher for exposed
children depending on the control group used. Researchers also found an association between
limb defects and exposure to valproate compared to other drugs used as an antiepileptic. 3
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Later, Werler 17 evaluated the use of specific antiepileptic drugs in pregnancy and their
relationship with congenital malformations. They used data from the National Birth Defects
Prevention Study, one of the most extensive studies on birth defects in the United States. They
assessed the use of these drugs and the risks posed for neural tube defects, oral clefts, heart
defects, hypospadias, a defect in male genitals, and other significant congenital disabilities. 18, 17
The authors found that increased risks that were drug-specific were observed for valproate.
These risks were associated with neural tube defects, oral clefts, heart defects, and hypospadias.
For example, mothers exposed to valproate were 9.7 times more likely to have a child with a
neural tube defect, 4.4 times more likely to have a child with an oral cleft, 2.0 times more likely
to have a heart defect, and 2.4 times more likely to have hypospadias. 17
Lastly, Weston et al. 11 assessed the effects of prenatal exposure to AEDs on the
prevalence of congenital malformations using several sources, including the Cochrane Epilepsy
Group Specialized Register and Medline. Prospective cohort studies, cohort studies set within
pregnancy registries, and randomized controlled trials were used. Fifty studies were included,
with 31 contributing to the meta-analysis. 11 The researchers found that children exposed to
valproate had the highest malformation risk levels than other AED. Children exposed to
valproate also had a higher risk than both groups of children in the control group versus children
exposed to the other AEDs. The malformation risk level was linked to the amount or dose of
valproate that the child was exposed to in utero. 11
Methods
This study is a retrospective cohort study. The researcher followed the sample
longitudinally through billing data using a billing ID, focusing on incidence rates based on the
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specified research questions as part of an epidemiological design. The research set to prove no
causal relationship but merely describe the distribution between the defined variables.
The study population came from the 2016-2018 MarketScan® Commercial Claims &
Encounters dataset obtained by the Medical University of South Carolina. This dataset was a
compiled set of 119 million privately insured individuals' billing records. The data were deidentified and examined by the IRB at MUSC and deemed non-human subjects.
Patients and Settings
The study sample was women of childbearing age, 18 to 44 years old, based on the CDC
indicator definition for reproductive health. 19 Inclusion criteria included women with three or
more months of valproate prescription fills. Exclusion criteria consisted of those not between 18
and 44 and those who had less than three (3) months of valproate prescribed. Insurance
information obtained from the MarketScan® data was 6 months pre-index and 12 months postindex, whereby the data index was the date from which the first valproate prescription was filled.
Aim
To examine the number of women of childbearing age (18-44) who were prescribed
valproate, some of their outcomes, and rates of pregnancy prevention to avoid risks resulting
from prenatal valproate exposure.
Under the aim, the project intended to answer the following research questions:
1) At what rate is valproate being prescribed to women of childbearing age?
Mawhinney 20 excluded women from their study who were missing data on drug dose and
administration. Since this study was not concerned with dosage, there were no exclusions
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whereby the research examined all billing data for valproate within the pre and post-index of
women ages 18-44.
2) What are the most common prescribing diagnoses (e.g., bipolar, epilepsy, migraines)?
The research was only interested in the three common diagnoses (bipolar, epilepsy, and
migraines) and therefore studied only the DSM-10 billing codes of F31.9 (bipolar), G40-G40.9
(Epilepsy), and G43-G43.9 (migraines).
3) For what age group of women is valproate most prescribed?
The research examined all billing data pertaining to women 18-44 years of age that fell
within the pre and post-index.
4) How many of those women prescribed valproate were part of a pregnancy prevention
program?
This interest area included whether the women were partaking in a pregnancy prevention
program as indicated by the ICD-10 CM codes of Z30-Z30.9 for contraceptive management
within their billing history.
5) Of those women taking valproate, how many later experienced a pregnancy?
For this area of interest, ICD-10 CM billing codes of Z32-Z32.3 were examined. Mawer
21

had no exclusions in their study but instead included every pregnancy known by women

attending the clinic. This study also used this logic. Of those pregnancies, the delivery outcome
(i.e., births) was also examined using the ICD-10 billing codes of Z37- Z37.9.
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Statistical Analysis
These data were analyzed using SAS version 9.4 (Cary, NC). Data are described using
measures of central tendency (mean, median, mode) and dispersion (standard deviation,
quartiles, min, max). The research describes and quantifies the number of pregnancies among
women 18-44 years of age on valproate in this epidemiological study. Tests for differences
between those on birth control and those not on birth control were made using Student’s t-test for
normally distributed data, Wilcoxon-Mann-Whitney for non-normally distributed data, and chisquared tests for categorical data. Statistical significance has been defined a priori to be <0.05.
Results
Table 3. Sample Characteristics

Clinical characteristics
Charlson comorbidity score

0.0 ± 0.0

Elixhauser conditions
Alcohol Abuse

2 (1.3)

Blood Loss Anemia

1 (0.7)

COPD

13 (8.7)

Cardiac Arrhythmia

3 (2.0)

Coagulopathy

2 (1.3)

Deficiency Anemia

7 (4.7)

Depression

35 (23.5)
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Diabetes, Complicated

2 (1.3)

Diabetes, Uncomplicated

5 (3.4)

Drug Abuse

6 (4.0)

Fluid/Electrolyte Disorder

2 (1.3)

Hypertension, Uncomplicated

14 (9.4)

Hypothyroidism

7 (4.7)

Obesity

13 (8.7)

Other Neurological Disorder

12 (8.1)

Psychoses

4 (2.7)

Pulmonary Circulation Disorder

1 (0.7)

Rheumatoid Arthritis

4 (2.7)

Weight Loss

3 (2.0)

All values expressed as n (%) mean ±s.d., or median [Q1 - Q3]

The women examined for the study were primarily healthy, with the most notable
characteristic being depression with n=23 (23.5%) of the sample. Other characteristics would not
be classified as significant.
For research question 1: At what rate is valproate being prescribed to women of
childbearing age, there were n=877 women aged 18-44 on valproate during 2016-2018. There
was n=318 women across 3 years of MarketScan ® data prescribed 3 or more months of the
drug. Of the 318 women, n=149 (46.8%) were analyzed for the study based on a 6-month preindex and 12-month post-index insurance.
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Figure 2. Valproates Prescribed

Valproates Prescribed
14.5%

Women of Child Bearing Age
Women Who Met Study Criteria

85.5%

For research question 2: What are the most common diagnoses (e.g., bipolar, epilepsy,
migraines), it was found that n=102 (68.4%) of the n=149 women were prescribed valproate for
one of the three diagnoses researched- there were no instances of multiple diagnoses within those
examined. Of those diagnoses, the most commonly prescribed was as a therapeutic for migraines
(n=50) followed by as a therapeutic for bipolar disorder (n=47).

Table 4. Diagnosis

Diagnosis

Frequency (n=102)

Bipolar

47 (31.5)

Epilepsy

23 (15.4)

Migraines

50 (33.6)

All values expressed as n (%)
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Figure 3. Common Diagnoses
Common Diagnoses

19.5%
31.5%

Bipolar
Epilepsy
Migraines
Other Diagnoses

33.6%

15.4%

For research question 3: For what age group of women is valproate most commonly
prescribed, the research showed that the average age for which valproate was prescribed was 34
years of age (standard deviation of 7.4), and the median age was 36 years of age.
Figure 4 Descriptive Statistics: Age of Women Represented in the Research
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Figure 5. Patient Age
Patient Age
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For research question 4: How many of those women prescribed valproate were part of a
pregnancy prevention program, the research showed that n=43 (28.9%) women were on one of
the three forms of birth control investigated, with the most common form being an oral
contraceptive (n=31). There was one billing ID that data showed was on both Depo and an IUD
within the data set.

Table 5. Contraceptives

Contraceptive (Any)

43 (28.9)

Contraceptive (Depo shot)

5 (3.4)

Contraceptive (IUD)

8 (5.4)

Contraceptive (Oral)

31 (20.8)

All values expressed as n (%)
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Figure 6. Contraceptive Use
Contraceptive Use
3.4%

5.4%

20.8%

Contraceptive (Depo shot)
Contraceptive (IUD)
Contraceptive (Oral)
No Contraceptive

70.5%

For research question 5: Of those women taking valproate, how many went on to
experience pregnancy, the research showed that of those women taking valproate, n=3 went on
to experience a pregnancy while there was n=1 recorded birth out of the n=149 women.

Table 6. Outcomes

Pregnancy

3 (2.0)

Birth

1 (0.7)

All values expressed as n (%)

Discussion
Of all the AEDs available, the use of valproate during childbearing years and pregnancy
has raised the most notable concerns. 9 FDA warnings related to valproate during pregnancy have
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emphasized the need for reassessment in its use clinically during these years. 9 Hence, despite its
known risks, valproate continues to be used in women of childbearing age as several pregnancy
registries have established the commonality of valproate to be prescribed. 9
Furthermore, a consensus is growing to reduce the number of women taking valproate.
This momentum comes from patient support groups and healthcare professionals based on the
expert advisory groups’ limited responses and variations of regulations regarding the drug’s use.
There are also mixed reactions among advocates, with reactions ranging from those advocating
shared decision making and informed patient choice to those advocating to bar the drug’s use in
pregnancy unless coupled with a pregnancy prevention program in those still taking the drug. 6
Moreover, the FDA's most recent guidance declares that valproate should not be
administered to women of childbearing age unless other medications have failed to provide
adequate symptom relief or are otherwise unacceptable. They continue by saying that in these
situations, effective contraception should be used. Ultimately there is no change from their
previous guidance in 2013.22. Notably, the research showed that 46.8% of the 318 women
prescribed valproate were of childbearing age and were prescribed 3 or more months of
valproate, whereby n=105 (70. 5%) of the sample were not on 1 of the 3 most common
contraceptive methods.
Equally important is a recent study by Tachibana et al.23, who investigated patterns in
psychiatrists’ prescriptions of valproate for bipolar female patients of childbearing age in Japan.
The reason for doing so was based on the global procedures that state valproate should not be
used for women of childbearing age. In this research, 571 psychiatrists responded to the survey,
with approximately 70% answering that they frequently or occasionally prescribed valproate for
bipolar women of childbearing age.23 Our study supported this finding, as valproate was most
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commonly prescribed for migraines followed by bipolar disorder. This despite research on the
effects of the drug being primarily focused on valproate as a therapeutic for epilepsy.
Meanwhile, the reason for the continued prescribing of valproate products is not yet
apparent.24 One possible explanation could be that the risks associated with prescribing valproate
have mainly been researched and limited to the epilepsy community, as mentioned previously,
with neurologists primarily reading this research. 24 Psychiatric journals, for instance, contain
only sporadic articles that may address the issue. Additionally, another main problem is that
guidelines lack a set of mandatory and required rules. For example, some guidelines call for
discussing the associated risks with those prescribed while paying attention to contraceptive use.
In contrast, others mention the guidance that valproate should not be used in women of
childbearing age unless other options have proven unsuitable and there is a contraception plan in
place. Ultimately, most of those guidelines associated with fetal risks focus solely on treating
women with epilepsy with the lack of awareness among psychiatrists and other practitioners.24
In conclusion, this research's findings highlight the importance of further education on
the risks of valproate and women of childbearing age. This is based on the lack of studies
focusing on the risks and prescribing patterns outside of the epilepsy community. Limitations to
the research included the length of contraceptive use and type of contraceptive use, such as
condom use, which the study could not account for. Ultimately, the researcher studied only
measurable pregnancy preventions (oral pills, intrauterine devices, transdermal patches) for this
research. Filtering this data did not increase the level of control for these factors. Furthermore,
future research could explore different funding streams as our research focused on commercial
payor billing data, which garnered a small sample size.

52

Manuscript References
1. Macfarlane, A., & Greenhalgh, T. (2018). Sodium valproate in pregnancy: What are the risks,
and should we use a shared decision-making approach? BMC Pregnancy and Childbirth, 18(1),
200–11.
2. Wyszynski, D. F., Nambisan, M., Surve, T., Alsdorf, R. M., Smith, C. R., & Holmes, L. B.
(2005). Increased rate of major malformations in offspring exposed to valproate during
pregnancy. Neurology, 64(6), 961–965.
3. Jentink, J., Loane, M., Dolk, H., Barisic, I., Garne, E., Morris, J., & de Jong-van den Berg, L.
(2010). Valproic acid monotherapy in pregnancy and major congenital malformations. The New
England Journal of Medicine, 362(23), 2185–2193. https://doi.org/10.1056/NEJMoa0907328
4. Koren, G., Nava-Ocampo, A. A., Moretti, M. E., Sussman, R., & Nulman, I. (2006). Major
malformations with valproic acid. Canadian Family Physician, 52(4), 441–447.
5. Adab, N., Jacoby, A., Smith, D., & Chadwick, D. (2001). Additional educational needs in
children born to mothers with epilepsy. Journal of Neurology, Neurosurgery & Psychiatry, 70(1),
15–21.
6. Angus-Leppan, H., & Liu, R. S. N. (2018). Weighing the risks of valproate in women who
could become pregnant. BMJ (Clinical research ed.), 361.
7. Velez-Ruiz, N. J., & Meador, K. J. (2015). Neurodevelopmental effects of fetal antiepileptic
drug exposure. Drug safety, 38(3), 271–278.
8. Gerard, E. E., & Meador, K. J. (2015). An update on maternal use of antiepileptic medications
in pregnancy and neurodevelopment outcomes. Journal of Pediatric Genetics, 4(2), 094–110.

53

9. Roullet, F. I., Lai, J. K., & Foster, J. A. (2013). In utero exposure to valproic acid and autism
— A current review of clinical and animal studies. Neurotoxicology and Teratology, 36, 47–56.
10. Alsdorf, R., & Wyszynski, D. F. (2005). Teratogenicity of sodium valproate. Expert Opinion
on Drug Safety, 4(2), 345–353.
11. Weston, J., Bromley, R., Jackson, C. F., Adab, N., Clayton-Smith, J., Greenhalgh, J.,
Hounsome, J., et al. (2016). Monotherapy treatment of epilepsy in pregnancy: Congenital
malformation outcomes in the child. Cochrane library, 2017(4)
12. Christensen, J., Grønborg, T. K., Sørensen, M. J., Schendel, D., Parner, E. T., Pedersen, L.
H., & Vestergaard, M. (2013). Prenatal valproate exposure and risk of Autism Spectrum
Disorders and Childhood Autism. JAMA, 309(16), 1696–1703.
13. Eriksson, K., Viinikainen, K., Mönkkönen, A., Äikiä, M., Nieminen, P., Heinonen, S., &
Kälviäinen, R. (2005). Children exposed to valproate in utero—Population-based evaluation of
risks and confounding factors for long-term neurocognitive development. Epilepsy
Research, 65(3), 189–200.
14. Tomson, T., Battino, D., Bonizzoni, E., Craig, J., Lindhout, D., Sabers, A., Perucca, E.,
Vajda, F. (2011). Dose-dependent risk of malformations with antiepileptic drugs: an analysis of
data from the EURAP epilepsy and pregnancy registry. Lancet Neurology, 10(7), 609–617.
15. Wyszynski, D. F., Nambisan, M., Surve, T., Alsdorf, R. M., Smith, C. R., & Holmes, L. B.
(2005). Increased rate of major malformations in offspring exposed to valproate during
pregnancy. Neurology, 64(6), 961–965.

54

16. Koren, G., Nava-Ocampo, A. A., Moretti, M. E., Sussman, R., & Nulman, I. (2006). Major
malformations with valproic acid. Canadian Family Physician, 52(4), 441–447
17. Werler, M. M., Ahrens, K. A., Bosco, J. L., Mitchell, A. A., Anderka, M. T., Gilboa, S. M.,
& Holmes, L. B. (2011). Use of antiepileptic medications in pregnancy in relation to risks of
birth defects. Annals of Epidemiology, 21(11), 842–850
18. Centers for Disease Control and Prevention (CDC). (2019a). Birth defects: hypospadias.
https://www.cdc.gov/ncbddd/birthdefects/hypospadias.html
19. Centers for Disease Control and Prevention. (2015). Chronic Disease Indicators:
Reproductive Health. Retrieved from https://www.cdc.gov/cdi/definitions/reproductivehealth.html
20. Mawhinney, E., Campbell, J., Craig, J., Russell, A., Smithson, W., Parsons, L., Robertson, I.,
et al. (2012). Valproate and the risk for congenital malformations: Is formulation and dosage
regime important? Seizure (London, England), 21(3), 215–218.
21. Mawer, G., Clayton- Smith, J., Coyle, H., & Kini, U. (2002). Outcome of pregnancy in
women attending an outpatient epilepsy clinic: adverse features associated with higher doses of
sodium valproate. Seizure (London, England), 11(8), 512–518.
22. The U.S. Food and Drug Administration (FDA). (2020). Highlights of Prescribing
Information.
https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018081s071,018082s054lbl.pdf
23. Tachibana, M., Hashimoto, T., Tanaka, M., Watanabe, H., Sato, Y., Takeuchi, T., Terao, T.,
et al. (2020). Patterns in Psychiatrists’ Prescription of Valproate for Female Patients of

55

Childbearing Age with Bipolar Disorder in Japan: A Questionnaire Survey. Frontiers in
psychiatry, 11, 250–250. Switzerland: Frontiers Media S.A.
24. Rakitin, A. (2020). Why Do Psychiatrists Still Prescribe Valproate to Women of
Childbearing Potential? Frontiers in psychiatry, 11, 739–739. Frontiers Media S.A.

56

Appendix
A: Contraceptives Studied
Description

National Drug Code (NDC)

Depo Shot

00009024802, 00009062601, 00009737611, 50090045900,
50090066500, 54868334801, 00009074630, 00009074635,
54569370100, 54569490400, 54569552700, 54868361300,
54868410000, 54868410001, 00009470913, 54569621900,
00548540000, 00548540025, 00548570100, 00703680101,
00703680104, 50090088300, 50090332800, 54569561600,
54569677100, 54868525700, 59762453701, 59762453702,
59762453802, 62756009040, 62756009045, 67457088700,
67457088701, 67457088799, 71205011801, 00548541000,
00548541025, 00548571100

Oral Contraceptive 00046257512, 51862023803, 52544095931, 54868491100,
76388028301, 00555905167, 00555905179, 51862007201,
51862007206, 52544094028, 00378729653, 00555905058,
00555905079, 54569582600, 54868474200, 00603751201,
00603751217, 00603751249, 51285012058, 54868473100,
00555904358, 00555904379, 50090248100, 54868475400,
50102015401, 50102015403, 50102025421, 50102025423,
00052026108, 54868386300, 00378728253, 00378728285,
16714036701, 16714036704, 00254203373, 00254203380,
00254203391, 00603754017, 00603754049, 54569645700,
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68180088211, 68180088213, 68180089111, 68180089113,
68180089171, 68180089173, 00781406615, 70700011384,
70700011385, 16714046401, 16714046404, 65862088728,
65862088788, 54868270100, 00093330416, 00093330428,
52544095428, 53217012728, 54569603200, 50419040901,
50419040903, 54868618300, 54868582800, 50419040701,
50419040703, 00781407515, 68180089411, 68180089413,
52544029831, 52544029841, 00378729953, 00378729985,
00378730053, 50090249400, 50090259400, 54569668800,
54569668900, 59746076342, 59746076343, 60505418301,
60505418303, 68180090211, 68180090213, 68462072029,
68462072084, 68462073329, 68462073384, 71205014428,
00093542328, 00093542358, 00093542362, 54569627200,
54868616200, 50102024021, 50102024023, 59651002928,
59651002988, 00781565615, 70700011484, 70700011485,
54569662200, 68180088611, 68180088613, 68180088671,
68180088673, 00555913167, 00555913179, 05559013179,
54569612800, 54868592200, 00781565815, 70700011584,
70700011585, 52544098228, 52544098231, 54569657600,
50419040201, 50419040203, 54569534900, 54868459000,
50419040501, 50419040503, 54569614400, 51862003603,
52544098131, 54569643400, 59651003028, 59651003085,
54868040400, 54868379000, 00378730653, 00378730753,

58

00378730785, 00555906458, 00555906479, 50090219100,
54569662400, 54868594200, 00093807316, 00093807328,
51862026001, 51862026006, 52544038328, 54569481700,
54868424000, 52544038428, 54868477800, 52544029528,
68462063729, 68462063784, 00905027721, 00905027928,
54868051800, 00905029128, 00555904758, 54868486000,
16714034001, 16714034002, 16714034004, 50090250500,
54569669000, 68180085711, 68180085713, 00603762517,
00603762549, 54569643600, 54868332800, 51862051006,
52544029128, 54569511500, 54868423900, 75854060202,
75854060203, 75854060228, 75854060101, 65862084928,
65862084988, 00781558315, 70700011684, 70700011685,
50102012001, 50102012003, 50102012010, 50102012048,
50102022021, 50102022023, 00555904558, 00555904579,
54868535600, 63187088928, 65862084828, 65862084888,
50102013001, 50102013003, 50102013010, 50102013048,
50102023021, 50102023023, 51660057286, 00378728753,
00378729853, 54569668600, 68180085411, 68180085413,
68180085471, 68180085473, 16714035901, 16714035903,
16714035904, 00781558436, 70700011787, 00555912366,
54868604400, 68180084411, 68180084413, 69238153106,
00555901467, 00555901479, 50419041112, 54868436800,
00378655053, 00378728153, 50090253400, 68180084311,

59

68180084313, 68462067291, 68462067295, 51862009701,
51862009706, 52544027928, 54569499700, 54868460700,
69238155406, 51862002801, 51862002806, 52544094928,
54569579800, 54868621000, 54569645500, 68462038829,
68462038884, 54868050700, 00254203273, 00254203280,
00254203291, 00603763417, 00603763449, 50090138000,
54569644200, 00555902058, 00555902079, 52544096691,
54569655600, 54868231600, 16714036601, 16714036603,
51862054501, 51862054506, 52544096728, 00781557515,
70700011884, 70700011885, 54569427301, 00378727753,
17478026106, 17478026128, 33261012001, 50090260300,
54569669600, 68180083811, 68180083813, 68180083871,
68180083873, 68462056529, 71205017028, 71205019128,
00062191000, 50458019106, 50458019115, 50458019128,
54868409300, 00062125100, 50458025106, 50458025115,
50458025128, 54569549300, 54569549302, 54868473000,
50090323900, 54569675800, 69238160706, 00781406015,
70700012184, 70700012185, 16714036301, 16714036304,
00781406215, 70700012084, 70700012085, 50090242900,
54569666700, 63187075428, 68180083711, 68180083713,
68180083771, 68180083773, 65862077828, 65862077885,
00093214028, 00093214062, 54569664100, 65862077728,
65862077785, 00254203080, 00254203091, 00603766317,
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54569628100, 54569628101, 00555901858, 50102023311,
50102023313, 50102023111, 50102023113, 52544024828,
54569579600, 54868582600, 52544008728, 52544008741,
00781405815, 70700011984, 70700011985, 17478026006,
17478026028, 50090225900, 50090345400, 68180084011,
68180084013, 69238155106, 65862077628, 65862077685,
16714036001, 16714036004, 52544024728, 54569581600,
00062190700, 50458019706, 50458019715, 50458019728,
54868260600, 00254202980, 00254202991, 00603764217,
54569628000, 54569628001, 00555901658, 53217009128,
54868482800, 63187091128, 50102023511, 50102023513,
55289088704, 63629266601, 52959046004, 00555904958,
00555904979, 50090218300, 54569662300, 54868485100,
16714036501, 16714036504, 54569067900, 54868042800,
55289024608, 51862056401, 51862056406, 52544084728,
54569499800, 52544084828, 51862004701, 51862004791,
52544026829, 52544026884, 51862004501, 51862004591,
52544022829, 50090209700, 54569662000, 68462064691,
68462064693, 00093313482, 00093313491, 00093614882,
00093614891, 68180084611, 68180084613, 68180086011,
68180086012, 00378728485, 00378728490, 00378728590,
00378731685, 51862048965, 68180084811, 68180084813,
51285009287, 54868627500, 51285043165, 51285043187,
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00093603182, 00093603191, 51285008782, 51285008787,
54868627600, 65862086494, 65862086495, 00430042014,
50090145600, 54569654200, 99999200020, 99999777602,
99999777605, 99999888981, 00025026506, 52544024531,
52544026531, 00555071558, 51862010201, 51862010206,
51862088401, 51862088403, 54868481400, 16714044001,
16714044004, 00555034458, 51862010001, 51862010006,
51862088601, 51862088603, 54569657500, 68462030329,
65862092528, 65862092585, 65862092587, 68180087711,
68180087713, 50102010001, 50102010003, 50102010010,
50102010048, 00062141101, 52544023528, 54868471200,
52544062928, 00378727253, 00378729253, 16714041301,
16714041304, 50090215000, 54569656500, 63187074828,
68180087611, 68180087613, 68462030529, 50090323500,
69238158306, 51660012786, 50458019406, 50458019416,
50458019428, 54868436900, 16714044101, 16714044104,
50102020011, 50102020013, 52544089228
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